NASDAQ:CASI CASI Pharmaceuticals Q3 2025 Earnings Results & Report $0.21 0.00 (0.00%) As of 10/9/2026 CASI Pharmaceuticals missed analyst earnings expectations in its Q3 2025 results, released November 14, 2025. The company reported EPS of -$0.67 versus the -$0.40 consensus estimate, while revenue was $3.08 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 14, 2025TimeBefore Market Opens CASI Pharmaceuticals EPS ResultsActual EPS-$0.67Consensus EPS -$0.40Beat/MissMissed by -$0.27One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersCASI Pharmaceuticals Revenue ResultsActual Revenue$3.08 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile CASI Pharmaceuticals Q3 2025 Earnings FAQ Did CASI Pharmaceuticals beat earnings estimates for Q3 2025? CASI Pharmaceuticals (NASDAQ:CASI) reported earnings of -$0.67 per share for Q3 2025, missing the consensus estimate of -$0.40. The report was announced on Friday, November 14, 2025. What was CASI Pharmaceuticals' revenue for Q3 2025? CASI Pharmaceuticals reported revenue of $3.08 million for Q3 2025. CASI Pharmaceuticals Earnings HeadlinesTheravance Biopharma (NASDAQ:TBPH) & CASI Pharmaceuticals (NASDAQ:CASI) Head-To-Head ContrastOctober 7, 2026 | americanbankingnews.comComparing Eloxx Pharmaceuticals (NASDAQ:ELOX) and CASI Pharmaceuticals (NASDAQ:CASI)October 4, 2026 | americanbankingnews.comMy biggest prediction yet?!James Altucher called Facebook's rise past 100 billion dollars in 2007 and Apple's run to a trillion years later, both times facing skepticism. Now he's tracking a new Elon Musk production facility that could begin operations as soon as October 21, tied to what he calls a potential 2 quadrillion dollar opportunity by 2040, based on Dallas Fed data. Altucher has put the full story and drone footage into one presentation.October 12 at 1:00 AM | Paradigm Press (Ad)CASI Pharmaceuticals stock plunges on Nasdaq delisting noticeFebruary 26, 2026 | za.investing.comWhat Drove CASI Pharmaceuticals' 24% Rise After Hours?February 26, 2026 | msn.comCASI Pharmaceuticals Fails to Renew FOLOTYN Import License in China, Halts SalesJanuary 24, 2026 | theglobeandmail.comSee More CASI Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CASI Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CASI Pharmaceuticals and other key companies, straight to your email. Email Address About CASI PharmaceuticalsCASI Pharmaceuticals (NASDAQ:CASI), Inc. is a biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company has historically concentrated on hematology and oncology, with operations spanning the United States and China. CASI’s commercial portfolio has included EVOMELA, an intravenous formulation of melphalan used in multiple myeloma treatment, including conditioning before autologous stem-cell transplantation and as a palliative therapy. The company has pursued commercialization and development opportunities in China through its local operating and distribution capabilities. In addition to commercial products, CASI has worked on innovative therapies such as cellular and targeted treatments for blood cancers. Its development activities have included partnerships and licensing arrangements designed to bring novel oncology medicines to patients, particularly in the Chinese market. CASI is headquartered in Rockville, Maryland, and maintains a significant focus on expanding its presence in China.View CASI Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsC.H. Robinson Bets Its AI Story on RXO—But the Market Isn't SoldApplied Digital’s Hidden Moat Could Unlock Massive Upside Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
